Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael J. Kelley, MD"'
Autor:
Katherine I. Zhou, MD, PhD, Chenyu Lin, MD, Chin-Lin Tseng, MPH, Nithya Ramnath, MBBS, Jonathan E. Dowell, MD, Michael J. Kelley, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 5, Pp 100670- (2024)
Introduction: The KRAS G12C inhibitor sotorasib was approved for treating advanced NSCLC in the second line or later on the basis of the CodeBreaK100 trial. Nevertheless, data on the real-world efficacy and safety of sotorasib, and to its optimal dos
Externí odkaz:
https://doaj.org/article/4f1e08331e2f48cd94d301fa4fe9842e
Autor:
Zhou KI; Katherine I. Zhou, MD, PhD, Division of Hematology-Oncology, Durham VA Medical Center, Durham, NC, Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC; and Michael J. Kelley, MD, Division of Hematology-Oncology, Durham VA Medical Center, Durham, NC, Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, National Oncology Program, Department of Veterans Affairs, Durham, NC., Kelley MJ; Katherine I. Zhou, MD, PhD, Division of Hematology-Oncology, Durham VA Medical Center, Durham, NC, Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC; and Michael J. Kelley, MD, Division of Hematology-Oncology, Durham VA Medical Center, Durham, NC, Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, National Oncology Program, Department of Veterans Affairs, Durham, NC.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2023 Sep; Vol. 7, pp. e2300275.
Autor:
Bates JS; Jill S. Bates, PharmD National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Department of Practice Advancement and Clinical Education, The University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, Pharmacy Service, Durham VA Medical Center, Durham, NC; Jennifer Piccolo, PharmD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Pharmacy Service, William S. Middleton Memorial Veterans Hospital, Madison, WI; Bailey Crandall, PharmD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Pharmacy Service, Ralph H. Johnson VA Medical Center, Charleston, SC; and Michael J. Kelley, MD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Hematology-Oncology, Durham VA Medical Center, Durham, NC, Department of Medicine, Duke Cancer Institute & Medical Oncology, Duke University, Durham, NC., Piccolo J; Jill S. Bates, PharmD National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Department of Practice Advancement and Clinical Education, The University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, Pharmacy Service, Durham VA Medical Center, Durham, NC; Jennifer Piccolo, PharmD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Pharmacy Service, William S. Middleton Memorial Veterans Hospital, Madison, WI; Bailey Crandall, PharmD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Pharmacy Service, Ralph H. Johnson VA Medical Center, Charleston, SC; and Michael J. Kelley, MD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Hematology-Oncology, Durham VA Medical Center, Durham, NC, Department of Medicine, Duke Cancer Institute & Medical Oncology, Duke University, Durham, NC., Crandall B; Jill S. Bates, PharmD National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Department of Practice Advancement and Clinical Education, The University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, Pharmacy Service, Durham VA Medical Center, Durham, NC; Jennifer Piccolo, PharmD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Pharmacy Service, William S. Middleton Memorial Veterans Hospital, Madison, WI; Bailey Crandall, PharmD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Pharmacy Service, Ralph H. Johnson VA Medical Center, Charleston, SC; and Michael J. Kelley, MD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Hematology-Oncology, Durham VA Medical Center, Durham, NC, Department of Medicine, Duke Cancer Institute & Medical Oncology, Duke University, Durham, NC., Kelley MJ; Jill S. Bates, PharmD National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Department of Practice Advancement and Clinical Education, The University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, Pharmacy Service, Durham VA Medical Center, Durham, NC; Jennifer Piccolo, PharmD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Pharmacy Service, William S. Middleton Memorial Veterans Hospital, Madison, WI; Bailey Crandall, PharmD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Pharmacy Service, Ralph H. Johnson VA Medical Center, Charleston, SC; and Michael J. Kelley, MD, National Oncology Program, Specialty Care Services, Department of Veterans Affairs, Washington DC, Hematology-Oncology, Durham VA Medical Center, Durham, NC, Department of Medicine, Duke Cancer Institute & Medical Oncology, Duke University, Durham, NC.
Publikováno v:
JCO oncology practice [JCO Oncol Pract] 2023 Aug; Vol. 19 (8), pp. 676-677. Date of Electronic Publication: 2023 Jun 30.
Autor:
Friedman DR; Daphne R. Friedman, MD, Division of Medical Oncology, Duke University School of Medicine, Durham, NC, Durham Veterans Administration Health Care System, Durham, NC; Ahmad S. Halwani, MD, George E. Wahlen Veterans Health Administration, Salt Lake City, UT, Division of Epidemiology, VERITAS, University of Utah, Salt Lake City, UT, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, Salt Lake City, UT; and Michael J. Kelley, MD, Division of Medical Oncology, Duke University School of Medicine, Durham, NC, Durham Veterans Administration Health Care System, Durham, NC, National Oncology Program Office, Department of Veterans Administration, Durham, NC., Halwani AS; Daphne R. Friedman, MD, Division of Medical Oncology, Duke University School of Medicine, Durham, NC, Durham Veterans Administration Health Care System, Durham, NC; Ahmad S. Halwani, MD, George E. Wahlen Veterans Health Administration, Salt Lake City, UT, Division of Epidemiology, VERITAS, University of Utah, Salt Lake City, UT, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, Salt Lake City, UT; and Michael J. Kelley, MD, Division of Medical Oncology, Duke University School of Medicine, Durham, NC, Durham Veterans Administration Health Care System, Durham, NC, National Oncology Program Office, Department of Veterans Administration, Durham, NC., Kelley MJ; Daphne R. Friedman, MD, Division of Medical Oncology, Duke University School of Medicine, Durham, NC, Durham Veterans Administration Health Care System, Durham, NC; Ahmad S. Halwani, MD, George E. Wahlen Veterans Health Administration, Salt Lake City, UT, Division of Epidemiology, VERITAS, University of Utah, Salt Lake City, UT, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, Salt Lake City, UT; and Michael J. Kelley, MD, Division of Medical Oncology, Duke University School of Medicine, Durham, NC, Durham Veterans Administration Health Care System, Durham, NC, National Oncology Program Office, Department of Veterans Administration, Durham, NC.
Publikováno v:
JCO clinical cancer informatics [JCO Clin Cancer Inform] 2022 Jul; Vol. 6, pp. e2200075.